As a result of this process, Synlogic will cease operations, and reduce its workforce by more than 90%, retaining only certain employees to assist in the strategic review and assist in the discontinuation of the study. The majority of impacted roles will end in February 2024….cash, cash equivalents and short-term investments balance at December 31, was $47.7M…
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SYBX:
- Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update
- Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria
- Synlogic reports publication of prelinical, clinical data for SYNB1353
- Synlogic Provides Corporate Update and Outlook for 2024
- Synlogic provides corporate update, outlook for 2024
